Susan Begelman, MD

Dr. Susan Begelman is the Vice President of the US Respiratory and Influenza Franchises at Genentech. In this role, she leads two cross-functional teams accountable for the development and implementation of integrated business and medical strategies focused on making medical progress for patients, addressing customer needs, and delivering on business objectives for these therapeutic areas.
Susan is widely regarded as a respected leader with an unwavering commitment to patients. She has fifteen years of experience in biopharmaceutical industry. Since joining Genentech in 2008, Susan has overseen product development activities and provided oversight of medical launch strategies and phase 3b/4 trials in multiple therapeutic areas that include cardiovascular disease, neuroscience, rare disease, and stroke. In her previous position, she was the Vice President of the Neuroscience, Rare Blood Disorders, Influenza, and Established Product Unit in US Medical Affairs. Prior to joining the biopharmaceutical industry, she was an academic vascular medicine physician in the Department of Cardiovascular Medicine and Medical Director of the Noninvasive Vascular Laboratory at the Cleveland Clinic for six years.
Susan received a Bachelor of Arts in Biology from the University of Pennsylvania and her Medical Doctorate from Hahnemann University School of Medicine (renamed Drexel University College of Medicine) in Philadelphia. She completed her residency in internal medicine and fellowship in vascular medicine at the Cleveland Clinic. Susan is a fellow of the Society for Vascular Medicine for which she was a Committee Chair and held elected positions as a Board of Trustees Member, Secretary, and Treasurer. Susan is also a fellow of the American College of Cardiology. In 2018, Dr. Begelman was appointed to the Board of Directors of the Genentech Foundation and is currently a Diversity and Inclusion Board member serving as an advisor to Genentech’s Chief Diversity Office.